First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, ...
In a randomized trial, 1 day of octreotide infusion combined with endoscopic therapy proved noninferior to 5 days for acute ...
People with inflammatory bowel disease, like ulcerative colitis, are 2 to 3 times more likely to develop blood clots than ...
When Phyllis Burk was diagnosed with Crohn’s disease nearly 50 years ago, it wasn’t as simple as looking up information ...
Annual fundraiser supports the foundation's efforts to raise awareness and improve quality of life for adults and children ...
Therapeutic drug monitoring is associated with better treatment durability among children with inflammatory bowel diseases.
The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...
The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...
The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...